Today, two pharmaceutical companies will be listed on the Growth Enterprise Market (GEM), with a total of nearly 1.2 billion yuan

【Pharma Network Pharmaceutical Stock Market】On October 13, 2022, the GEM Listing Committee of Shenzhen Stock Exchange held the 73rd listing committee review meeting in 2022, and two companies, Anhui Wanbang Pharmaceutical Technology Co.
, Ltd.
(hereinafter referred to as "Wanbang Pharmaceutical") and Jiaxing Kaishi Biotechnology Co.
, Ltd.
(hereinafter referred to as "Kaishi Biotechnology") will be reviewed for IPO on
the Growth Enterprise Market (GEM).
It is reported that the two companies intend to raise a total of nearly 1.
2 billion yuan, of which Wanbang Pharmaceutical intends to raise 484 million yuan and Kaishi Biologics intends to raise 700 million yuan
.
Founded in 2006, Wanbang Pharma is engaged in a one-stop CRO (contract research organization) service platform
for the whole process of pharmaceutical development to clinical research of innovative drugs, improved new drugs and generic drugs.
It aims to provide drug development and clinical trials for drug marketing, including pharmaceutical research, clinical services, biological sample analysis and testing, SMO services and data statistics and analysis
.
For this listing, Wanbang Pharma intends to issue no more than 16,666,667 shares to the public and plans to raise 484 million yuan, of which 404 million yuan will be used for the drug research and development and pharmacokinetic engineering center project, including clinical trial service capacity improvement project, pharmaceutical research center upgrade construction project and innovative drug development platform construction project
.
80 million yuan for replenishment of working capital projects
.
In terms of financial data, Wanbang Pharma expects to achieve operating income in the first three quarters of this year in the range of 172 million yuan to 190 million yuan, a year-on-year increase of 12.
09% to 23.
89%; The net profit attributable to the shareholders of the parent company ranged from 59.
375 million yuan to 65.
625 million yuan, a year-on-year increase of 0.
18% to 10.
72%.

。 In addition, according to the data, from 2019 to 2021 and the first half of 2022 (reporting period), Wanbang Pharma achieved operating income of 103 million yuan, 139 million yuan, 211 million yuan and 108 million yuan respectively, and net profit of 26.
49 million yuan, 54.
5156 million yuan, 81.
8703 million yuan and 35.
8254 million yuan respectively.
Kaishi Biologics According to the data, Kaishi Biologics was established in June 2009.
It is a company that provides customized solutions for in vitro diagnostic instruments and consumables, and is a third-party R & D and manufacturing enterprise
for in vitro diagnostic instruments and consumables.
In this IPO, Kaishi Biologics intends to raise 700 million yuan, which will be used for in vitro diagnostic product production base projects, in vitro diagnostic instrument research and development projects and supplementary working capital
.
Among them, the in vitro diagnostic product production base project, also known as the CDMO R&D center, instrument and consumables production base project with an annual output of 3,000 sets of in vitro diagnostic medical instruments and 3 billion pieces of medical consumables, has a planned investment of 441 million yuan and plans to invest 420 million yuan
.
According to the prospectus, Kaishi Biologics has set up three R&D centers in Jiaxing, Shanghai and Hangzhou, and has accumulated a number of core technologies
in the field of in vitro diagnostic instruments and consumables.
In terms of financial data, during the reporting period from 2019 to 2021, Kaishi Biologics achieved operating income of 132 million yuan, 259 million yuan and 573 million yuan respectively, and net profit of 17.
5324 million yuan, 66.
852 million yuan and 124 million yuan
respectively.
However, it is worth noting that in 2020 and 2021, the company's consumables revenue increased by 362.
49% and 213.
96% respectively, accounting for 47.
13% and 66.
60%
of the main business income.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.